NEW YORK, Nov. 8, 2017 /PRNewswire/ -- If you want a Stock Review on AMRN, ENDP, IONS, or TEVA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pharmaceutical manufacturers compete to discover and commercialize ever-more effective medicines. Companies focus on the most profitable markets, where demand for treatment is high. This morning, DailyStockTracker.com shifts focus on four Drug Manufacturers equities to see how they have fared over the previous trading sessions: Amarin Corp. PLC (NASDAQ: AMRN), Endo International PLC (NASDAQ: ENDP), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at: http://dailystocktracker.com/register/
AmarinDublin, Ireland-based Amarin Corp. PLC's stock finished Tuesday's session 2.73% lower at $3.56 with a total trading volume of 907,992 shares. Over the last month and the previous three months, the Company's shares have advanced 2.30% and 6.59%, respectively. Additionally, the stock has gained 15.58% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 6.10% and 7.43%, respectively. Moreover, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 61.14.
On November 01st, 2017, Amarin announced financial results for the three months ended September 30th, 2017. Net product revenue for Q3 2017 was $47.1 million; gross margin on product sales improved to 75%; and GAAP net loss was $10.8 million. At September 30th, 2017, the Company reported cash and cash equivalents of $79.1 million. Your complete research report on AMRN can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=AMRN
Endo InternationalShares in Dublin, Ireland headquartered Endo International PLC dropped 4.97%, ending yesterday's session at $5.93. A total volume of 7.79 million shares was traded, which was above their three months average volume of 6.90 million shares. The stock is trading 26.88% below its 50-day moving average. Moreover, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 32.20.
On October 25th, 2017, Endo International announced the completion of the previously announced sale of Grupo Farmacéutico SOMAR to Advent International for a purchase price of approximately $124 million, after giving effect to estimated cash, debt, and net working capital purchase price adjustments. A free report on ENDP is just a click away at: http://dailystocktracker.com/registration/?symbol=ENDP
Ionis PharmaceuticalsOn Tuesday, Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock saw a correction of 3.59%, to close the day at $52.30. A total volume of 1.55 million shares was traded, which was above their three months average volume of 1.37 million shares. The Company's shares have advanced 8.82% in the previous three months and 9.35% on an YTD basis. The stock is trading 6.30% above its 200-day moving average. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 40.35.
On November 06th, 2017, Ionis Pharma announced that it submitted a new drug application to the US Food and Drug Administration (FDA) for inotersen, an investigational medicine for the treatment of patients with hereditary TTR amyloidosis (hATTR), a severe, rare, and fatal disease. Inotersen is under regulatory review for marketing authorization in the U.S. and EU. The FDA has granted Orphan Drug Designation and Fast Track Status to inotersen for the treatment of patients with polyneuropathy due to hATTR. Sign up for your complimentary research report on IONS at: http://dailystocktracker.com/registration/?symbol=IONS
Teva Pharmaceutical IndustriesShares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd ended the day 5.80% lower at $11.69. A total volume of 31.37 million shares was traded, which was above their three months average volume of 26.62 million shares. The stock is trading below its 50-day moving average by 25.92%. Furthermore, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 30.34.
On November 02nd, 2017, Teva announced that it has completed the sale of Plan B One-Step® and the Company's value brands of emergency contraception to Foundation Consumer Healthcare in a $675 million cash transaction.
On November 07th, 2017, research firm HSBC Securities downgraded the Company's stock rating from 'Hold' to 'Reduce'. Register for free on DailyStockTracker.com and download the latest research report on TEVA at: http://dailystocktracker.com/registration/?symbol=TEVA
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: (207) 331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
AmarinDublin, Ireland-based Amarin Corp. PLC's stock finished Tuesday's session 2.73% lower at $3.56 with a total trading volume of 907,992 shares. Over the last month and the previous three months, the Company's shares have advanced 2.30% and 6.59%, respectively. Additionally, the stock has gained 15.58% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 6.10% and 7.43%, respectively. Moreover, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 61.14.
Advertisement
On November 01st, 2017, Amarin announced financial results for the three months ended September 30th, 2017. Net product revenue for Q3 2017 was $47.1 million; gross margin on product sales improved to 75%; and GAAP net loss was $10.8 million. At September 30th, 2017, the Company reported cash and cash equivalents of $79.1 million. Your complete research report on AMRN can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=AMRN
Endo InternationalShares in Dublin, Ireland headquartered Endo International PLC dropped 4.97%, ending yesterday's session at $5.93. A total volume of 7.79 million shares was traded, which was above their three months average volume of 6.90 million shares. The stock is trading 26.88% below its 50-day moving average. Moreover, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 32.20.
On October 25th, 2017, Endo International announced the completion of the previously announced sale of Grupo Farmacéutico SOMAR to Advent International for a purchase price of approximately $124 million, after giving effect to estimated cash, debt, and net working capital purchase price adjustments. A free report on ENDP is just a click away at: http://dailystocktracker.com/registration/?symbol=ENDP
Ionis PharmaceuticalsOn Tuesday, Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock saw a correction of 3.59%, to close the day at $52.30. A total volume of 1.55 million shares was traded, which was above their three months average volume of 1.37 million shares. The Company's shares have advanced 8.82% in the previous three months and 9.35% on an YTD basis. The stock is trading 6.30% above its 200-day moving average. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 40.35.
On November 06th, 2017, Ionis Pharma announced that it submitted a new drug application to the US Food and Drug Administration (FDA) for inotersen, an investigational medicine for the treatment of patients with hereditary TTR amyloidosis (hATTR), a severe, rare, and fatal disease. Inotersen is under regulatory review for marketing authorization in the U.S. and EU. The FDA has granted Orphan Drug Designation and Fast Track Status to inotersen for the treatment of patients with polyneuropathy due to hATTR. Sign up for your complimentary research report on IONS at: http://dailystocktracker.com/registration/?symbol=IONS
Teva Pharmaceutical IndustriesShares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd ended the day 5.80% lower at $11.69. A total volume of 31.37 million shares was traded, which was above their three months average volume of 26.62 million shares. The stock is trading below its 50-day moving average by 25.92%. Furthermore, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 30.34.
On November 02nd, 2017, Teva announced that it has completed the sale of Plan B One-Step® and the Company's value brands of emergency contraception to Foundation Consumer Healthcare in a $675 million cash transaction.
On November 07th, 2017, research firm HSBC Securities downgraded the Company's stock rating from 'Hold' to 'Reduce'. Register for free on DailyStockTracker.com and download the latest research report on TEVA at: http://dailystocktracker.com/registration/?symbol=TEVA
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: (207) 331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/drug-makers-stock-performance-review----amarin-endo-ionis-pharma-and-teva-pharma-300551765.html
SOURCE dailystocktracker.com
